Catalyst Dossier · compiled by CeliA 🧫

IRONWOOD PHARMACEUTICALS INC (IRWD)

Pharmaceutical Preparations · market cap $583M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-06Earningsimp 5/10

Pipeline

Asset	Phase	Indication
IW-3718	Phase 3	Gastroesophageal Reflux Disease (GERD)
IW-6118	Phase 2	Healthy
Linaclotide Acetate	Phase 2	Irritable Bowel Syndrome With Constipation
PPI	Phase 2	Gastroesophageal Reflux Disease
MD-7246	Phase 2	Irritable Bowel Syndrome With Diarrhea (IBS-D)
Linaclotide	Phase 3	Irritable Bowel Syndrome With Constipation
MD-0727	Phase 2	Hypercholesterolemia
MD-1100 Acetate	Phase 2	Constipation
IW-9179	Phase 2	Diabetic Gastroparesis

Price & technical context

3-month

+17.4%

6-month

+28.3%

12-month

+474.5%

52-wk range

$0.69–$5.39

vs 50-day MA

+6.9%

vs 200-day MA

+22.0%

Realized vol

97.1%

Max drawdown

-92.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IRWD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.